Disease Biomarker Detection
Disease Biomarker Detection - Related Videos
07:32
A Capillary Electrophoresis Immunoassay for Protein Biomarker Detection
0 Views •
2025
This video demonstrates a capillary electrophoresis immunoassay protocol for detecting a protein biomarker associated with amyotrophic lateral sclerosis (ALS) from human blood platelets. Confirmation of the presence of the ALS biomarker protein is achieved through size-based separation of the platelet proteins followed by chemiluminescent detection.
03:04
Colorimetric Detection of a Bacterial Biomarker Using a Modified Litmus Test
0 Views •
2025
This video demonstrates a colorimetric E. coli detection method, involving an E. coli biomarker activating a DNAzyme, leading to cleavage of RNA linkage and detachment of a DNAzyme-urease conjugate. A subsequent colorimetric assay detects the E. coli biomarker through ammonia-induced pH changes.
09:00
High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
0 Views •
Cited by 14 •
2012
High throughput validation of multiple candidate biomarkers can be performed by sequential ELISA in order to minimize freeze/thaw cycles and use of precious plasma samples. Here, we demonstrate how to sequentially perform ELISAs for six different validated plasma biomarkers1-3 of graft-versus-host disease (GVHD)4 on the same plasma sample.
12:52
Iridium(III) Luminescent Probe for Detection of the Malarial Protein Biomarker Histidine Rich Protein-II
0 Views •
Cited by 4 •
2015
Robust detection reagents are of increasing necessity for developing new malaria diagnostic tools. An iridium(III) probe was designed that emits long-lasting luminescent signal in the presence of a histidine-rich malarial protein biomarker. Detection of the protein either in solution or immobilized on a magnetic particle affords flexibility in application.
10:22
Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
0 Views •
Cited by 59 •
2016
High Frequency Oscillations (HFOs) have emerged as presurgical biomarkers for the identification of the epileptogenic zone in pediatric patients with medically refractory epilepsy. A methodology for the noninvasive recording, detection, and localization of HFOs with simultaneous scalp electroencephalography (EEG) and magnetoencephalography (MEG) is presented.
FAQs
The assay format determines how a molecular signal is generated and quantified. Antibody-antigen assays rely on binding between the target and antibody, nucleic-acid assays use amplification, enzymatic assays measure reaction-associated signals, and mass spectrometry separates molecules before measurement. These alternatives let investigators analyze different biomarker properties in biological samples.
A measured signal has meaning only when compared with an appropriate reference or clinical threshold. This comparison helps distinguish a biomarker value associated with disease-related change from a value within the expected reference context. It also supports assessment of diagnostic value, disease progression, or response to treatment rather than relying on an isolated measurement.
Interpretation depends on what the measurement is being compared against and what clinical question it addresses. Relative to reference samples or established thresholds, results can indicate disease presence or risk; evaluated alongside disease course or treatment, they can reveal progression or response. Thus, the same biochemical measurement may support different conclusions in different contexts.
A typical workflow analyzes a biological sample such as blood, tissue, or another sample type with a suitable biochemical assay. The assay generates a measurable signal through binding, amplification, an enzymatic reaction, or molecular separation. That signal is then quantified and compared with reference samples or clinical thresholds to produce an interpretable result.
Its uses extend beyond identifying disease. Measurements can support early diagnosis, estimate disease risk, monitor progression, evaluate response to treatment, and help stratify patients into biologically meaningful groups. In research, the same information contributes to drug development by showing how disease-associated biology changes and whether an intervention produces a measurable effect.
Biochemistry connects a measured signal to the molecular event being analyzed, whether that event involves antibody-antigen binding, nucleic-acid amplification, an enzymatic reaction, or mass spectrometric separation. This molecular context helps researchers study disease mechanisms, relate biomarker changes to treatment response, and develop more personalized approaches to care.